news, journals and articles from all over the world.
In a study published in Nature Communications, researchers at Sylvester Comprehensive Cancer Center have shown that whole genome sequencing can help determine which patients with a multiple myeloma precursor condition, called MGUS or smoldering myeloma, progress to full-blown cancer
Read more
DALLAS – March 8, 2021 – A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial with UT Southwestern as the lead enrolling site.
Read more
Dr. Cherry focused on results from a Juno Therapeutics phase 2 study of liso-cel, an investigational CAR T therapy being tested against aggressive relapsed/refractory B cell non-Hodgkin lymphoma. Early results indicate a good safety profile, with few adverse events reported. Dr. Cherry also presented on the final results of a phase 1 study of targeted therapy gilteritinib in newly diagnosed acute myeloid leukemia (AML). Gilteritinib targets the most common mutation that causes AML, the FLT3 gene. Gilteritinib is sold under the brand name Xospata® by Astellas Pharma.
Read more
UC San Diego study supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multiple myeloma.
Read more
— A group of researchers led by Maximillian Merz, MD, Assistant Professor of Oncology with the Myeloma team at Roswell Park Comprehensive Cancer Center, conducted the first prospective clinical trial investigating spatial heterogeneity in patients with either relapsed/refractory or newly diagnosed multiple myeloma. Findings from the study will be presented today at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which is being held virtually.
Read more
Dana-Farber Cancer Institute, one of the world’s leading centers of cancer research and treatment, and Quest Diagnostics, (NYSE: DGX), the world’s leading provider of diagnostic information services, announced the start of a new research study that provides free COVID-19 antibody testing to individuals who are at high risk of developing multiple myeloma.
Read moreMD Anderson and Allogene today announced a strategic five-year collaboration for preclinical and clinical investigation of allogeneic CAR T cell therapies.
Read moreAs we celebrate National Nurses Week, Memorial Sloan Kettering Cancer Center (MSK) and The Robbins Family Foundation recognize seven distinguished nursing staff members for their exemplary service. Each member of this select group is being honored with the inaugural 2020 Robbins Family Award for Nursing Excellence.
Read more
Dana-Farber Cancer Institute will establish the Riney Family Multiple Myeloma Initiative to help improve outcomes and accelerate understanding of the underlying biology for the most challenging types of myelomas, cancers that form in a type of white blood cell called a plasma cell.
Read moreAn experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies
Read more